Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz

Research at the site focuses on reducing the risk of recurrent ischemic stroke and high‑risk transient ischemic attacks. Studies aim to test novel antithrombotic agents, evaluate long‑term vascular health, and improve functional recovery after acute events.

• Prevention of recurrent ischemic events
• Evaluation of novel antithrombotic agents
• Assessment of functional outcomes after acute stroke
• Safety monitoring of bleeding risk
• Long‑term vascular health improvement

Gyor‑Moson‑Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz contributes valuable data to cardiovascular research in Europe.

The hospital conducts a broad oncology program that includes trials for immunotherapy and targeted treatments across hematologic and solid tumors such as chronic lymphocytic leukemia, multiple myeloma, diffuse large B‑cell lymphoma, esophageal carcinoma, metastatic prostate cancer, and non‑small cell lung cancer. The goal is to enhance survival, delay disease progression, and personalize therapy based on molecular profiles.

• Combination immunotherapy trials
• Targeted therapy in solid tumors
• Novel antibody‑drug conjugates
• Personalized treatment based on genetic markers
• Neoadjuvant strategies to enhance surgical outcomes

This research hub in Győr is advancing cancer care through collaborative multi‑center studies.

Clinical investigations address progressive lung scarring, including idiopathic pulmonary fibrosis and related conditions. Trials evaluate new antifibrotic compounds with the aim of preserving forced vital capacity and improving quality of life for patients with chronic pulmonary fibrosis.

• Antifibrotic drug efficacy
• Long‑term safety in fibrotic lung disease
• Biomarker‑driven patient selection
• Quality‑of‑life assessments
• Pulmonary function preservation

The Győr research facility plays a key role in advancing therapies for respiratory diseases in Hungary and beyond.